Project Grant R03CA296049
Award Date
7/2/25
Completion Date
6/30/27
Dollars Obligated
$164K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $125,783.00 to The University of Texas MD Anderson Cancer Center to conduct research on advanced gastric adenocarcinoma (GAC). The key objectives are to: 1) Determine the mechanisms of CDH1-inactivated advanced GAC progression, focusing on the roles of SOX4 and EZH2; and 2) Evaluate molecular subtype-based responses to immune checkpoint blockade. The research leverages murine organoid...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $764,565 to the Sloan-Kettering Institute for Cancer Research to conduct a large prospective investigation to validate promising metabolite biomarkers for gastric cancer risk and discover novel biomarkers. The 5-year project will harmonize pre-diagnostic plasma samples and epidemiological data from ~1,200 gastric cancer cases and 1,600 matched controls across six...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $483,000 to the University of California, Davis to advance the understanding of genomically stable (GS) gastric tumors, which disproportionately affect the Latino population. The key objectives are to: Characterize the epigenome of 100 Latino GS gastric tumors using reduced representation bisulfite sequencing (RRBS). Investigate GS tumor biology using Latino gastric organoids and isogenic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...
This Cooperative Agreement award, with a total funding of $1,069,873, was granted by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The award aims to establish the Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D) to develop a multimodal, single-cell, dynamic, and 3D spatial atlas of normal-appearing gastric mucosa, early precancerous lesions, and advanced gastric cancer in individuals with...
The National Cancer Institute (NCI) awarded a $564,414 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant will fund a 5-year research project to: 1) Develop and validate a predictive model based on electronic health record data that can accurately identify individuals at high risk for gastric cancer, and 2) Develop a mathematical model to assess the potential...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower program (CFDA 93.398), supports research by Vanderbilt University to investigate the role of the transcription factor SOX9 in the development of gastric cancer. The $183,758 award from September 2024 to May 2025 will fund experiments to determine if SOX9 is required for gastric chief cells to transdifferentiate into spasmolytic polypeptide-expressing metaplastic (SPEM) cells, which are...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,774,998.00 to the Coriell Institute for Medical Research, Inc., a non-profit biomedical research center, to conduct research on exosomal galectin-3 mediated stromal activation and immunosuppression in advanced gastric adenocarcinoma. The award, effective from September 30, 2024 to September 29, 2027, supports the institute's innovative scientific...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...
This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...